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Abstract
Purpose The prognostic differences between right- and
left-sided colon cancer are controversial. This study aimed
to clarify the clinical difference between right- and left-
sided colon cancer.
Methods We enrolled 820 patients with stage I/II/III
colon cancer who underwent radical surgery with curative
intent. We explored the impact of the tumor location on the
postoperative disease-free survival (DFS) rate using the
univariate and multivariate analyses.
Results Right-sided disease occurred in 399 of the 820
patients. The mean follow-up period was 55.8 ±
34.9 months. The pathological stage distribution was as
follows: stage I 261 patients; stage II 283; and stage III
251. There were no significant differences in the five-year
DFS of the overall populations (right 88.6 %; left 89.4 %;
P = 0.231). The subgroup analyses demonstrated that
patients with stage I right-sided colon cancer had a sig-
nificantly better 5-year DFS rate than did those with left-
sided disease (100 vs. 95.2 %, P = 0.034). There were no
significant differences in the distributions of the first
recurrent sites (P = 0.559).
Conclusions The tumor location may contribute to post-
operative tumor recurrence. However, these effects were
inconsistent across tumor stages. Our results provide a
better understanding of the prognostic disparity between
tumor locations; this may improve patient consent and
postoperative surveillance.
Keywords Colon carcinoma  Proximal colon 
Distal colon  Prognosis  Recurrence
Introduction
Colon cancer is one of the most common malignancies
worldwide, and despite improvements in the treatments for
locally advanced and metastatic disease, colon cancer is the
third leading cause of cancer-related deaths in Japan. Vital
Statistics Japan (Ministry of Health, Labour and Welfare)
estimated that 42,800 deaths were attributable to colon
cancer in Japan in 2009.
Based on the incipient differences between right- and left-
sided colon cancer, the relevance of the tumor location in the
postoperative prognosis of colon cancer has been explored for
a few decades. Several single-institutional cohort studies
published in the 1980s concluded that the tumor location had
no impact on the overall survival [1, 2], whereas recent
nationwide cohort studies demonstrated that right-sided colon
cancer was associated with a worse overall survival than was
left-sided colon cancer [3–7]. A better understanding of the
site-specific survival outcomes would be helpful for guiding
research and education, but the influence of the tumor location
on the survival outcomes remains unclear.
The impact of the tumor stage and location on the survival
outcomes is also imprecise. A large American retrospective
cohort study, namely, the surveillance, epidemiology, and
end results (SEER) program, showed that patients with stage
II right-sided colon cancer had a significantly lower hazard
ratio (HR) than did patients with left-sided colon cancers;
patients with stage III and IV right-sided colon cancer had a
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significantly higher HR than did patients with the same stage
of left-sided colon cancer [6]. To understand these distinc-
tive results, it is important to identify the patterns of recur-
rence according to the tumor stage and location. However,
only one study has so far examined the patterns of postop-
erative recurrence by tumor location, reporting systemic and
local recurrence without describing the organs affected by
the colon cancer metastasis [4].
The aim of the present study was to examine the dif-
ferences in oncological behavior according to the tumor
location in colon cancer, using a single institutional Japa-
nese database without racial diversity. The results will be
helpful to many surgeons for developing treatment strate-
gies and in the patient consent process.
Methods
The procedures used for including patients are shown in
Fig. 1. Between January 1990 and January 2006, 1,694
patients with colon cancer were treated surgically at our
institute; 820 underwent radical surgery with curative
intent for colon cancer, and these formed the basis of our
study. Histopathological staging was confirmed postoper-
atively by a consulting pathologist through examinations of
retrieved specimens.
The tumor location from the cecum to the sigmoid colon
was classified by the TNM criteria 6th edition. The cecum
and the ascending and transverse colon were defined as the
right-sided colon, whereas the descending and sigmoid
colon were defined as the left-sided colon. We excluded
patients receiving preoperative chemo- or radiotherapy,
which can affect the postoperative survival.
The demographic variables examined included the age,
sex, year of diagnosis, stage, histological grade, and
number of lymph nodes examined in the surgical specimen.
Survival data were confirmed at every hospital visit or by
telephone.
This study was approved by the ethics review board in
our institute.
Surveillance program
All patients were followed up according to our scheduled
surveillance program, which mainly consisted of physical
examination, measurement of the serum tumor markers
(carcinoembryonic antigen (CEA) and carbohydrate anti-
gen 19-9 [CA 19-9]), computed tomography, and colon-
oscopy. Patients with stage I cancer were followed up
every 6 months with physical examinations, measurement
of the serum tumor marker levels (CEA and CA 19-9) and
computed tomography. For patients with stage II and III
cancer, the serum tumor marker levels were examined
every 3 months and computed tomography was performed
every 6 months for up to 5 years. Colonoscopy was per-
formed 1 year after the operation and every 3 years
thereafter for all patients. Postoperative surveillance was
usually discontinued for patients without any relapse at
6 years after surgery, but it was continued in this case at
the request of the patient.
Fig. 1 A flow chart of the
patient inclusions between
January 1990 and January 2006
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Statistical methods
The continuous data were analyzed using Student’s t test.
Differences in continuous variables were compared by testing
the differences in the medians by the Kruskal–Wallis test. The
survival analysis was performed by the Kaplan–Meier
method, and the log-rank test was used to determine the sta-
tistical significance of differences. Cox proportional hazard
methods were used to assess the multivariate predictors of
outcomes. All statistical tests were two-sided, and a value of
P = 0.05 was considered to be statistically significant. The
statistical analyses were performed using the SPSS software
program (version 17, SPSS, Chicago, Illinois).
Results
Patient characteristics
The patient characteristics are shown in Table 1. Right-
sided disease was present in 49 % (399/820) of the
included patients. The mean patient age was
64.2 ± 11.6 years; 497 participants (60.6 %) were males.
The pathological stage distribution was as follows: 261
individuals had stage I disease; 283, stage II disease; and
251, stage III disease. The patients with right-sided colon
cancers were significantly older (right-sided 65.9 ±
11.2 years; left-sided 62.2 ± 11.8; P \ 0.001) and exhib-
ited a poorer performance status (0/1/2/3/4; right-sided,
224/88/14/3/2 vs. left-sided, 264/72/6/5/0; P = 0.032),
than those with left-sided disease. There was a significant
difference in the length of the operation between the groups
(right-sided 175.6 min vs. left-sided 187.3 min; P =
0.023). Moreover, the primary tumors differed significantly
in terms of the proportion of poorly differentiated adeno-
carcinoma (right-sided 26/386 vs. left-sided 11/413;
P = 0.011), tumor size (right-sided 4.6 ± 2.7 cm vs. left-
sided 3.8 ± 2.0; P \ 0.001), and tumor stage (stage I/II/
III; right-sided, 110/147/131 vs. left-sided, 151/136/120;
P = 0.032). The mean number of retrieved lymph nodes
was 21.8 in cases of right-sided colon cancer and 16.4 in
cases of left-sided disease (P \ 0.001). There was no
Table 1 The patient backgrounds
Variables Right Left Total P value
Number of patients 399 421 820
Baseline variables
Age Mean ± SD 65.97 ± 11.3 62.23 ± 11.9 64.25 ± 11.6 \0.001
Gender Male/female 250/149 247/174 497/323 0.243
Body mass index Mean ± SD 22.91 ± 3.6 22.36 ± 3.3 22.63 ± 3.6 0.052
Performance status 0 224 264 488 0.037
1/2 88/14 72/6 160/20
3/4 3/2 5/0 8/2
Family history Yes/no 38/340 43/362 81/702 0.796
Surgery-related variables
Length of operation Mean ± SD 175.6 ± 78.0 187.3 ± 78.0 182.5 ± 76.8 0.023
Estimated blood loss Mean ± SD 144.4 ± 217.7 146.9236.5 140.8 ± 218.8 0.955
Emergency operation Yes/no 3/391 5/412 8/803 0.726a
Laparoscopic surgery Yes/no 152/243 176/244 328/487 0.319
Pathological variables
Tumor size Mean ± SD 4.6 ± 2.7 3.8 ± 2.0 4.2 ± 2.4 \0.001
Pathological grade wel/mod 360 402 762 0.011
por/muc/sig 26 11 37
Others 5 2 7
TNM stage I 110 151 261 0.032
II 147 136 283
III 131 120 251
Number of harvested LNs Mean ± SD 21.8 ± 13.1 16.4 ± 11.3 19.3 ± 12.5 \0.001
Number of metastatic LNs Mean ± SD 1.2 ± 2.7 0.8 ± 1.8 0.96 ± 2.2 0.027
Use of adjuvant chemotherapy Yes/no 115/284 115/306 0.631b
SD standard deviation, wel well-differentiated tubular adenocarcinoma, mod moderately differentiated tubular adenocarcinoma, por poorly differentiated
tubular adenocarcinoma, muc mucinous adenocarcinoma, sig signet-ring cell adenocarcinoma, LN lymph node
a Fisher’s exact test
b Chi square test
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significant difference in the postoperative use of adjuvant
chemotherapy (Chi square test, P = 0.631) (Table 2).
Difference in the DFS of colon cancer based
on the tumor location
The mean follow-up period in the overall population of
patients was 55.8 ± 34.9 months; the three-year and five-
year DFS rates were 88.6 and 85.2 % in right-sided colon
cancer patients and 89.4 and 88.4 % in left-sided colon
cancer patients, respectively. There was no significant
difference between the two groups (log-rank, P = 0.231;
Fig. 2). Compared to left-sided colon cancer, the unad-
justed hazard ratio (HR) for right-sided colon cancer was
estimated to be 1.253 (95 % confidence interval (CI),
0.837–1.874), while the HR adjusted by age, performance
status, size, and TNM stage was estimated to be 0.948
(95 % CI, 0.592–1.518). Moreover, the adjusted HRs were
estimated to be 1.096 (95 % CI, 0.657–1.827) for cecum or
ascending colon cancer, 0.760 (95 % CI, 0.330–1.749) for
transverse colon cancer, and 1.152 (95 % CI, 0.476–2.785)
for descending colon cancer (Table 3).
We added the subgroup analyses to assess the influence
of differences in the baseline characteristics. The subgroup
analyses demonstrated that patients with right-sided colon
cancer had a significantly better five-year DFS than did the
patients with left-sided disease (100 vs. 95.2 %,
P = 0.034) at stage I. However, there was no significant
difference at stages II and III (right-sided 79.4 %; left-
sided 84.7 %, P = 0.152; Figs. 3, 4).
Details of recurrence and treatment after recurrence
Postoperative recurrence developed in 94 patients, 50 of
whom had right-sided colon cancer. The details of the
Table 2 The patient backgrounds stratified by stage
Variables Stage I Stage II/III
Right (n = 110) Left (n = 151) P value Right (n = 278) Left (n = 256) P value
Baseline variables
Age Mean ?/SD 64.8 ± 10.8 61.4 ± 11.3 0.014 66.4 ± 11.7 62.6 ± 12.0 0.003
Gender Male/female 77/33 55/96 0.278 168/110 144/115 0.242
Body mass index Mean ± SD 23.1 ± 3.2 22.9 ± 3.2 0.630 22.9 ± 3.7 22.1 ± 3.3 0.055
Performance status 0 70 106 0.206 151 154 0.159
1/2 19/2 24/0 64/12 44/6
3/4 0/0 0/0 3/2 4/0
Family history Yes/no 14/90 15/136 0.450 22/244 26/244 0.405
Pathological variable
Tumor size Mean ± SD 2.8 ± 2.5 2.2 ± 1.2 0.008 5.1 ± 2.5 4.6 ± 1.9 0.001
Pathological grade wel/mod 105 144 0.483 251 250 0.006
por/muc/sig 2 3 24 8
Others 0 2 3 0
Number of harvested LNs Mean ± SD 16.6 ± 12.4 11.7 ± 11.2 0.001 23.9 ± 12.8 19.5 ± 10.1 \0.001
Number of metastatic LNs Mean ± SD – – – 1.6 ± 3.1 1.2 ± 2.1 0.069
SD standard deviation, wel well-differentiated tubular adenocarcinoma, mod moderately differentiated tubular adenocarcinoma, por poorly
differentiated tubular adenocarcinoma, muc mucinous adenocarcinoma, sig signet-ring cell adenocarcinoma, LN lymph node
Fig. 2 The five-year disease-free survival rate of patients with right-
and left-sided colon cancer. There was no significant difference
between right- and left-sided disease (right 85.2 %; left 88.4 %;
P = 0.231)
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recurrent sites by each tumor location are shown in
Table 4. There were no significant differences in the dis-
tribution of the first recurrent sites between tumor locations
(Chi square test, P = 0.559). The treatment after recur-
rence included salvage surgery in 26 (27.7 %) patients and
systemic chemotherapy in 22 (23.4 %); there was no sig-
nificant difference in the treatment after recurrence
between the tumor locations (Chi square test, P = 0.753).
Discussion
Our data show that right-sided colon cancer had a mar-
ginally worse DFS rate than left-sided cancer. This asso-
ciation between the tumor location and DFS was especially
clear in advanced colon cancer (stage II or III), but was
inconsistent for patients with stage I disease. Furthermore,
there was no significant difference in the distribution of the
first recurrence site between the patients with right- and
left-sided disease.
Although the overall survival rate was defined as a
primary endpoint in previous studies assessing the prog-
nostic difference between tumor locations, we used the
DFS rate as a primary endpoint for two reasons. First, the
DFS rate, which is calculated based on tumor recurrence,
describes the metastatic potential more precisely than does
the overall survival rate. Second, there is a paucity of
evidence regarding the patterns of recurrence based on
tumor location. Our results on the DFS rate lead to a better
understanding of the prognostic differences between right-
sided and left-sided colon cancer, and can improve patient
management.
One large cohort study reported that the prognostic
disparity according to tumor location was inconsistent
Table 3 The results of the multivariate survival analysis based on the
tumor location
Colon site Hazard ratioa 95 % CI P value
Cecum and ascending colon 1.096 0.657–1.827 0.148
Transverse colon 0.760 0.330–1.749 0.547
Descending colon 1.152 0.476–2.785 0.540
Sigmoid colon 1
a Hazard ratio (HR) adjusted by age, performance status, size and
TNM stage
Fig. 3 The five-year disease-free survival rate of patients with right-
and left-sided colon cancer in stage I. Patients with right-sided colon
cancer had a significantly better survival rate (100 vs. 95.2 %,
P = 0.034)
Fig. 4 The five-year disease-free survival rate of patients with right-
and left-sided colon cancer in stages II/III. There was no significant
difference between right- and left-sided disease (right 79.4 %; left
84.7 %; P = 0.152)
Table 4 The site of recurrence of right- and left-sided colon cancer
Variables Right Left Total P value
Number of patients with
recurrence
51 39 90 0.272
Site of recurrence











Bone 1 (2 %) 2 (5 %) 3






Resection rate (%) 25.4 33.3 28.9 0.625
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across tumor stages, similar to our results [6]. Although the
reasons for this disparity are unclear, some oncological
data may be pertinent. Advanced right-sided colon cancers
were more significantly associated with poorly differenti-
ated adenocarcinoma than were left-sided cancers. This
differential prevalence of poorly differentiated adenocar-
cinoma may contribute to the worse prognosis of right-
sided advanced colon cancer. In addition, the negative
association between right-sided colon cancer and recur-
rence disappeared in early stage colon cancers. This sug-
gests that right-sided colon cancers acquire worse
oncological potential in late stages of tumor development.
Furthermore, tumors with microsatellite instability, which
more frequently develops in right-sided colon cancer, have
been associated with better prognosis; this may explain the
reduction of recurrence [8–10]. A better understanding of
these disparate results will require the use of a prospective
database with a large number of patients and including
more clinical and pathological details.
During embryologic development, the right colon arises
from the midgut and the left colon from the hindgut. The
right and left colons are exposed to different luminal
contents. Consequently, many studies have been conducted
to explore these theoretical genetic backgrounds of the
different lesions. Although BRAF mutations were reported
to be a risk factor for metastatic spread, peritoneal metas-
tases, and distant lymph node metastases [11], BRAF
mutations were observed more frequently in the proximal
colon [12]. In addition, the genome-wide analyses using
primary tumor specimens have revealed differential gene
expression patterns in both tumor locations. These studies
may be useful for identifying prognostic differences, but
future investigations addressing prognostic biomarkers are
required to acquire robust data and to improve the post-
operative surveillance and treatment.
There are some differences between Japanese and
Western colorectal cancer (CRC) screening systems. In
Japan, although the approach to CRC screening remains
centered on the use of fecal immunochemical testing, most
patients diagnosed with CRC are recommended to undergo
total colonoscopy. On the other hand, in the US, there has
been a shift toward a more complex approach to CRC
screening, in which options such as fecal occult blood testing
and colonoscopy are regularly employed. However, US
experts did not recommend colonoscopy for CRC screening
until 2002, and sigmoid scope examinations were mainly
performed for patients diagnosed with CRC [13, 14]. The
percentage of early disease detected in the right colon
increased significantly, from 22.1 to 24.1 %, after Medicare
approved colonoscopy for CRC screening, indicating that
colonoscopy improved the early detection of proximal
tumors [15]. Clarification of the influence of nation health
systems on cancer-related mortality requires future
investigation of global cancer statistics and health systems.
These reasons may also explain why the rate of stage I right-
sided colon cancer was high, at 27.5 %, in our study.
Most previous studies have focused on Western popu-
lations and demonstrated no racial disparity in the tumor
recurrence or cancer-related death based on the tumor
location. However, there is a paucity of data concerning the
relationship between the tumor location and survival out-
comes in Asian patients. A recent South Korean study
found that left-sided colon cancer was a risk factor for
recurrence as well as the preoperative CEA level, T-stage,
N-stage, and use of postoperative chemotherapy in a
multivariate analysis, in contrast to the Western data and
our present results [16]. Another study reported that Asian
patients had better overall survival than did non-Hispanic
white and black patients [5]. However, these analyses were
performed based on a database established in Western
countries and containing a small number of enrolled cases
of racial minorities [17]. Further investigations of non-
Western populations are required to explore the impacts of
the tumor location on the prognostic disparity.
There are some limitations to our study that should be
kept in mind when interpreting the results. Although most
previous studies assessed similar outcomes using a
nationwide database [3–7], the statistical power of our
study is somewhat weak due to the retrospective nature of
the analysis, the fact that the data were from a single
institution and the relatively small sample size included in
the analysis. Moreover, despite the availability of modern
powerful chemotherapy for CRC patients [18, 19], the
impact of adjuvant chemotherapy on CRC has not been
evaluated, leading to significant heterogeneity resulting
from changing regimens. The patients analyzed in this
study have been collected retrospectively over 17 years,
and during this time the health care environment with
regard to the treatment of colorectal cancer patients,
including the use of postoperative chemotherapy, has
changed a lot. This study showed that there was no sig-
nificant difference in the use of postoperative adjuvant
chemotherapy between the groups; however, it may be
better to evaluate the status of postoperative chemotherapy
and chemotherapy for recurrent cancer separately.
Although one previous study reported that the incidence of
synchronous liver metastasis differs between proximal and
distal colon cancer, there were no significant differences in
the distribution of the first recurrence site between right-
and left-sided diseases in our data [20].
Another limitation of this study is the failure to deter-
mine the cause(s) of the observed disparity, because an
exploratory data analysis (perhaps leading to identification
of a crucial gene) was not performed.
In conclusion, compared to left-sided colon cancer,
right-sided colon cancer is a marginally significant risk
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factor for recurrence in patients with advanced colon can-
cer (stage II or III). In contrast, right-sided colon cancer at
stage I has a significantly better prognosis. Furthermore,
there are no differences in the distribution of the first
recurrent site based on the primary tumor location. Our
results provide a better understanding of the prognostic
disparity between tumor locations; this may improve
patient consent and postoperative surveillance.
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